What is Athens Research & Technology?
Athens Research & Technology operates as a critical infrastructure provider in the biotechnology landscape, focusing on the high-precision purification of human proteins and enzymes. By delivering essential components such as coagulation factors, immunoglobulins, and specialized enzymes, the company serves as a vital partner for pharmaceutical scientists, diagnostic manufacturers, and academic researchers. Their commitment to maintaining high purity and biological activity in their protein offerings enables advancements in the study of complex conditions, including autoimmune diseases and inflammatory pathways. Through its dual focus on human and animal-derived proteins, the company maintains a versatile product portfolio that supports both small-scale research initiatives and large-scale diagnostic kit production.
How much funding has Athens Research & Technology raised?
Athens Research & Technology has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Athens Research & Technology
PPP
Public-Private Partnership
What's next for Athens Research & Technology?
With this late-stage financing, Athens Research & Technology is poised to scale its production capacity and enhance its custom purification service offerings. The strategic allocation of this capital will likely prioritize the optimization of laboratory workflows and the expansion of its distribution network to meet the growing demand for high-quality biological reagents. As the company transitions into this next phase of growth, it remains focused on maintaining its reputation for quality and innovation, ensuring that its research-grade proteins continue to facilitate breakthroughs in medical diagnostics and therapeutic development. The firm is expected to leverage this financial momentum to solidify its competitive advantage in the global protein purification market.
See full Athens Research & Technology company page
